| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Soyasapogenol A targets hepatocytes and inflammatory pathways involved in liver damage. It directly prevents apoptosis of hepatocytes. The compound inhibits the elevation of plasma TNF-α, a key inflammatory cytokine involved in hepatitis. Soyasapogenol A protects against the concanavalin A-induced hepatitis immune response. It also induces apoptosis in Hep-G2 hepatocellular carcinoma cells. Its mechanism involves both anti-apoptotic effects on normal hepatocytes and pro-apoptotic effects on cancer cells.
|
|---|---|
| ln Vitro |
In vitro, Soyasapogenol A directly prevents apoptosis of hepatocytes. It inhibits the elevation of TNF-α in cell culture systems. The compound induces apoptosis in Hep-G2 hepatocellular carcinoma cells. Soyasapogenol A has been studied in various cell lines including U2OS, SKOV3, and Saos-2. Its hepatoprotective effects have been demonstrated in cell-based assays using hepatocyte cultures. The compound's anti-inflammatory activity is assessed by measuring TNF-α production.
|
| ln Vivo |
In vivo, Soyasapogenol A prevents liver damage in the Concanavalin A-induced hepatitis model. It directly prevents apoptosis of hepatocytes and inhibits the elevation of plasma TNF-α. The compound protects against the concanavalin A-induced hepatitis immune response. Soyasapogenol A is a natural triterpene compound isolated from soybean. Its hepatoprotective and anti-inflammatory effects have been demonstrated in animal models. Further in vivo studies are ongoing to fully characterize its therapeutic potential.
|
| Enzyme Assay |
Soyasapogenol A hepatoprotective assays involve measuring prevention of hepatocyte apoptosis and inhibition of TNF-α elevation. Hepatocyte apoptosis is assessed by measuring caspase activity or Annexin V staining in hepatocyte cultures. TNF-α levels are measured by ELISA in cell culture supernatants or plasma samples. For the Concanavalin A-induced hepatitis model, liver damage markers such as ALT and AST are measured. Anti-inflammatory activity is assessed by measuring inhibition of pro-inflammatory cytokine production. Assays are performed in appropriate buffer systems with positive controls.
|
| Cell Assay |
Soyasapogenol A cell-based assays are conducted in hepatocytes, Hep-G2 cells, and other cell lines. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with Soyasapogenol A at varying concentrations. Cell viability is assessed by MTT or CCK-8 assays. Apoptosis is evaluated by Annexin V/PI staining and caspase activity assays. TNF-α levels are measured by ELISA. For hepatoprotection studies, cells are treated with apoptotic inducers and protection is assessed. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
Soyasapogenol A in vivo studies are conducted in the Concanavalin A-induced hepatitis model in mice. Animals are treated with Soyasapogenol A via oral administration or injection. Liver damage is assessed by measuring serum ALT and AST levels. Hepatocyte apoptosis is assessed by TUNEL assay or caspase activity measurement in liver tissue. Plasma TNF-α levels are measured by ELISA. Liver histopathology is performed to assess tissue damage. Dosing regimens are optimized based on pharmacokinetic data. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biochemical analysis at study endpoints. Studies are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
Soyasapogenol A (MW 474.72 g/mol) is a triterpene compound. It is soluble in DMSO and other organic solvents. The compound is stable under recommended storage conditions. Soyasapogenol A is isolated from soybean and from the roots of Abrus cantoniensis. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution would be determined in species-specific studies. The compound is typically used in hepatoprotective and anti-inflammatory research.
|
| Toxicity/Toxicokinetics |
Soyasapogenol A is generally well-tolerated in preclinical studies at therapeutic doses. The compound is a natural triterpene from soybean with a well-characterized safety profile. Its hepatoprotective and anti-inflammatory effects have been demonstrated with acceptable safety profiles. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References | |
| Additional Infomation |
Soyasapogenol A is a pentacyclic triterpenoid compound belonging to the oleanane type. It contains a double bond between positions 12 and 13, with hydroxyl groups substituted at positions 3β, 21β, 22β, and 24. It is derived from the hydride of oleanane. Soyasapogenol A has been reported to exist in soybean (Glycine max), kudzu (Pueraria montana var. lobata), and other organisms with relevant data.
Soyasapogenol A is a triterpene compound isolated from soybean that directly prevents apoptosis of hepatocytes and inhibits plasma TNF-α elevation. It prevents liver damage in the Concanavalin A-induced hepatitis model. Soyasapogenol A protects against the concanavalin A-induced hepatitis immune response and induces apoptosis in Hep-G2 cells. It is a natural triterpene with hepatoprotective and anti-inflammatory activities. All applications are limited to non-human research use. |
| Molecular Formula |
C30H50O4
|
|---|---|
| Molecular Weight |
474.71600
|
| Exact Mass |
474.371
|
| CAS # |
508-01-0
|
| PubChem CID |
12442849
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
308-312 °C
|
| LogP |
5.082
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
34
|
| Complexity |
881
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
C[C@]12CC[C@@H]([C@]([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC([C@H]([C@H]5O)O)(C)C)C)C)C)(C)CO)O
|
| InChi Key |
CDDWAYFUFNQLRZ-KJVHGCRFSA-N
|
| InChi Code |
InChI=1S/C30H50O4/c1-25(2)16-19-18-8-9-21-27(4)12-11-22(32)28(5,17-31)20(27)10-13-30(21,7)29(18,6)15-14-26(19,3)24(34)23(25)33/h8,19-24,31-34H,9-17H2,1-7H3/t19-,20+,21+,22-,23-,24+,26+,27-,28+,29+,30+/m0/s1
|
| Chemical Name |
(3R,4S,4aR,6aR,6aS,6bR,8aR,9S,10S,12aR,14bS)-9-(hydroxymethyl)-2,2,4a,6a,6b,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-3,4,10-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~210.65 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (5.27 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.27 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1065 mL | 10.5325 mL | 21.0650 mL | |
| 5 mM | 0.4213 mL | 2.1065 mL | 4.2130 mL | |
| 10 mM | 0.2107 mL | 1.0533 mL | 2.1065 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
